Floatz logo

Disitamab

Cutaneous Paget Disease

Explore 1 assets in Cutaneous Paget Disease →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Fudan University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06561555CT.gov
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Cutaneous Paget Disease

AssetSponsorPhaseRating
Disitamab (this asset)Fudan UniversityP2CCC · 53

Other indications for Disitamab

IndicationSponsorPhaseRating
Non-Small Cell Lung Carcinoma—P2CCC · 55
HER2 Positive Breast Carcinoma—P2CCC · 53
Ovarian Carcinoma—P2CCC · 53

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Disitamab in Cutaneous Paget Disease. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/disitamab-cutaneous-paget-disease

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →